Two Cancer Specialists on White House Commission on CAM

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

WASHINGTON-President Clinton included two cancer specialists on the newly created, 11-member White House Commission on Complementary and Alternative Medicine: George M. Bernier, Jr., MD, hematologist/oncologist, University of Texas Medical Branch in Galveston, and William R. Fair, MD, of Long Boat Key, Fla, former chief of the urology service, Memorial Sloan-Kettering Cancer Center, and emeritus professor of urology, Weill Medical College of Cornell University.

WASHINGTON—President Clinton included two cancer specialists on the newly created, 11-member White House Commission on Complementary and Alternative Medicine: George M. Bernier, Jr., MD, hematologist/oncologist, University of Texas Medical Branch in Galveston, and William R. Fair, MD, of Long Boat Key, Fla, former chief of the urology service, Memorial Sloan-Kettering Cancer Center, and emeritus professor of urology, Weill Medical College of Cornell University.

The commission is charged with developing legislative and administrative recommendations aimed at maximizing the benefits of contemporary and alternative medicine (CAM). Psychiatrist James S. Gordon, MD, director, Center for Mind-Body Medicine, Washington, will chair the commission.

Other members include Sister Charlotte Rose Kerr, RN, of Baltimore, a traditional acupuncture practitioner; Wayne B. Jonas, MD, of the Uniformed Services University of Health Sciences and former director of the NIH Office of Alternative Medicine; Dean Ornish, MD, of Sausalito, California, founder of the Preventive Medicine Research Institute; and George Thomas DeVries III, of Rancho Santa Fe, California, president and CEO of American Specialty Health.

Also, Joseph J. Fins, MD, director of medical ethics, New York Weill Cornell Medical Center; Conchita M. Paz, MD, of Las Cruces, NM, a family medicine specialist; Buford L. Rolin, of Atmore, Alabama, health administrator for the Poarch Band of Creek Indians; Julia Scott, of Washington, DC, president of the National Women’s Health Project; and Thomas Chappell, of Kennebunk, Maine, co-founder of Tom’s of Maine.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.